Skip to main content

Identification of a chromatin regulator signature and potential candidate drugs for bladder cancer



Bladder cancer (BLCA) is a malignant tumor with a dismay outcome. Increasing evidence has confirmed that chromatin regulators (CRs) are involved in cancer progression. Therefore, we aimed to explore the function and prognostic value of CRs in BLCA patients.


Chromatin regulators (CRs) were acquired from the previous top research. The mRNA expression and clinical information were downloaded from TCGA and GEO datasets. Cox regression analysis and least absolute shrinkage and selection operator (LASSO) regression analysis were performed to select the prognostic gene and construct the risk model for predicting outcome in BLCA. The Kaplan-Meier analysis was used to assess the prognosis between high- and low-risk groups. We also investigated the drug sensitivity difference between high- and low-risk groups. CMAP dataset was performed to screen the small molecule drugs for treatment.


We successfully constructed and validated an 11 CRs-based model for predicting the prognosis of patients with BLCA. Moreover, we also found 11 CRs-based model was an independent prognostic factor. Functional analysis suggested that CRs were mainly enriched in cancer-related signaling pathways. The CR-based model was also correlated with immune cells infiltration and immune checkpoint. Patients in the high-risk group were more sensitive to several drugs, such as mitomycin C, gemcitabine, cisplatin. Eight small molecule drugs could be beneficial to treatment for BLCA patients.


In conclusion, our study provided novel insights into the function of CRs in BLCA. We identified a reliable prognostic biomarker for the survival of patients with BLCA.


Bladder cancer (BLCA), as a worldwide health issue, is one of the malignancies with significant sex discriminations that incidence and mortality are approximately 4 times higher among men than in women [1]. Despite encouraging achievements being accomplished in diagnosis and treatment, including liquid biopsy, targeted therapy, and immunotherapy, the overall survival of BLCA patients remains to be unsatisfactory [2,3,4,5,6,7,8,9]. Accumulating evidence has confirmed that multigene signature could offer risk stratification and prognostic prediction in cancer [10,11,12,13,14]. Therefore, this research aims to build a chromatin regulator signature to forecast the overall survival of patients with BLCA.

Epigenetic alterations, which were considered as one of the most significant hallmarks of tumors, were actuated by chromatin regulators (CRs). CRs were indispensable regulatory elements of epigenetics [15]. CRs were mainly classified into three categories based on roles in epigenetics: DNA methylators, histone modifiers, and chromatin remodelers [16]. But these three categories were closely associated with each other when involved in biological processes. Further studies have revealed that the aberrant expressions of CRs were implicated in multiple biological processes including inflammation [17], apoptosis [18], autophagy [19], and proliferation [20], which indicated that CRs deregulation could result in the development of many diseases including cancer. CRs have been proved to be abnormally expressed and associated with outcomes across cancer types. HMGA1, belonging to chromatin remodeler, was obviously elevated in BLCA, and HMGA1 deletion attenuated the proliferation, invasion, and activated the autophagy by regulating miR-221/TP53INP1/p-ERK1/2 pathway [21]. CBX7, a member of chromobox family with epigenetic regulation, has been found to be downregulated in BLCA, especially in patients with high grade, advanced T and N stage [22]. Furthermore, the overexpression of CBX7 was correlated with longer survival. CBX7 overexpression inhibited the malignant progression of BLCA cells via transcriptional regulating AKR1B10/ERK signaling. WDR5, a crucial member of the MLL/SET1 complexes with methyltransferase activity, has been reported to be markedly upregulated in BLCA, and the overexpression of WDR5 was associated with advanced tumor stage and shorter survival [23]. Further in vitro and in vivo experiments suggested that WDR5 promoted tumor growth and enhanced the chemoresistance of tumor cells to cisplatin. ZNF671, as a DNA methylator, inhibited cell growth and invasion in BLCA [24]. EZH2, a histone lysine methyltransferase, was implicated in diverse malignant phenotypes such as apoptosis and metastasis in multiple types of cancers [25,26,27].

A better understanding of CRs is crucial for BLCA progression and therapy, as well as paving the way for further research. However, few pieces of researches have been systematically explored the relationship between CRs and BLCA. In this study, we focused on investigating the expression profiles and prognostic values of CRs in BLCA through bioinformatic analysis. We successfully constructed and proved a prognostic signature based on 11 CRs, which could effectively predict the outcome of BLCA patients. Furthermore, we found the relationship between the prognostic signature and the immune microenvironment in BLCA, providing a theoretical basis for the immune checkpoint therapy strategies. In addition, we also found 8 small molecule drugs that might be beneficial for treatments of BLCA patients.

Materials and Methods

Data collection and identification of differentially expressed CRs

The mRNA expression and relevant clinical information of 19 normal bladder tissues and 414 bladder cancer tissues were obtained from the public database (the Cancer Genome Atlas, TCGA, A total of 870 Chromatin regulators (CRs) were retrieved from previous topic research [15]. We also downloaded GSE13507 [28] consisting of 165 bladder cancer tissues from a public database (Gene Expression Omnibus, GEO, for the validation. These mRNA expression profiles were normalized through the corresponding R package. According to the criteria of |logFC| >1 and false discovery rate (FDR) < 0.05, differentially expressed CRs were identified by limma package based on R software.

Functional enrichment analyses and protein-protein interaction (PPI)

Gene Ontology (GO) analysis, including molecular function (MF), biologic process (BP), and cellular components (CC), was performed through the ClusterProfiler package. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was conducted with the same method. FDR and p < 0.05 were regarded as significantly enriched. We submitted the differently expressed CRs to the STRING database ( to obtain protein-protein interaction information. Cytoscape software was used to construct and visualize the PPI network. We implemented the MCODE plug-in to select the most significant module of the PPI network by MCODE scores > 10.

Screening for potential small molecule drugs

We uploaded differently expressed CRs into the Connectivity MAP database (CMAP, to screen potential small molecule drugs related with CRs for treatments of BLCA patients. Scores were set from −1 to 1 to assess the degree of closeness in the compound-related with uploaded genes. Drugs with negative scores could exert the anti-cancer function. And the set threshold was p < 0.01, n ≥ 3, percent non-null =100 and enrichment < -0.8.

Construction and validation of a prognostic model based on CRs

We performed univariate Cox regression analysis to further screen the prognostic value of CRs. Then lasso-penalized Cox regression analysis were utilized to construct the prognostic risk model through glmnet R package. Risk scores were calculated by the following tool:

$$\mathrm{Risk}\ \mathrm{score}=\left(\mathrm{Coef}1\ast \mathrm{expression}\ \mathrm{mRNA}1\right)+\left(\mathrm{Coef}2\ast \mathrm{expression}\ \mathrm{mRNA}2\right)+\left(\mathrm{Coef}\ \mathrm{n}\ast \mathrm{expression}\ \mathrm{mRNA}\ \mathrm{n}\right)$$

where Coef is lasso Cox regression model coefficient of the corresponding mRNA. We divided BLCA patients into high-risk groups and low-risk groups in accordance with the median risk score. Survival analysis was performed by using Kaplan-Meier curve to evaluate the prognosis in two groups. Time-related ROC analysis was applied to assess the prognostic ability of the risk model via survivalROC package. A GEO dataset was considered as the validated set for further verification of the prognostic performance of this model.

Gene Set Enrichment Analysis (GSEA)

To investigate the underlying molecular mechanisms among low- and high-risk groups, Gene Set Enrichment Analysis (GSEA) analysis was conducted. P value < 0.05 and FDR < 25% were considered statistically significant.

Nomogram establishment based on risk score and clinical variables

We researched the relationship between CR-based signature and Clinical variables. In addition, combined with other clinical variables, we performed univariate and multivariate Cox regression analyses for exploring whether risk scores had an independent prognostic value in BLAC patients. Clinical variables and the CR-based signature risk score were applied to establish a nomogram associated with outcome for evaluating the probability of 3-, and 5-year OS for BLCA patients. The concordance index (C-index) and calibration curve were performed to assess the predictive utility of the nomogram.

Immune cell infiltration analysis

Mounting research confirmed that tumor cells immune infiltration was involved in

cancer progression and correlated with prognosis. Therefore, we evaluated the infiltration level of immune cells between high-risk groups and low-risk groups based on B cell-specific lncRNA signature by using CIBERSORT, CIBERSORT-ABS, QUANTISEQ, MCP-counter, XCELL, TIMER, and EPIC algorithms. In order to predict the effect of immune checkpoint blockade therapy, we also explored the expression of several immune checkpoints such as PDCD1, HAVCR2 (Tim-3), PD-L1, LAG3, TIGIT, and CTLA4. In addition, the TIMER database ( was used to identify the relationship between immune cells and 11 CRs and improve our understanding of the role of CRs in BLCA.

Drug sensitivity analysis

To explore the sensitivity difference of drugs between two groups, we used the Genomics of Drug Sensitivity in Cancer (GDSC, database to analyze the half-maximal inhibitory concentration (IC50) of drugs for predicting the drug sensitivity by using the package (pRRophetic). P values < 0.05 were considered statistically significant.

Statistics analysis

All statistical analyses were conducted by R software (version 4.0.5). The Wilcoxon test was used to compare the differences among the two groups. P-value < 0.05 was considered statistically significant.


Establishment and validation of CR-based signature

Compared with the normal bladder tissues, a total of 91 CRs, including 38 down-regulated CRs and 53 up-regulated CRs, were identified as differently expressed CRs in the TCGA-BLCA dataset (Figure 1). Based on these deregulated CR, we used univariate Cox regression analysis to explore the prognostic value of CR. The result showed that only 12 of them had prognostic merit (Figure 2). Then, LASSO Cox regression analysis was used to construct a signature for prognostic prediction capacity of BLCA patients. A risk model was successfully constructed with 11 genes (ZHX3, TCF4, SETD7, HMGA1, ARID3A, RAC3, DUSP1, SETBP1, CBX7, RCOR2, and SATB1). The risk score was calculated by relevant coefficients of 11 CRs as following formula (Table 1): risk score= (0.3622 × ZHX3 expression) +(0.1749 × TCF4 expression) + (0.1362 × SETD7 expression) + (0.0711 × HMGA1 expression) + (0.1523 × RAC3 expression) + (0.0217 × DUSP1 expression) + (0.0721 × ARID3A expression) + (0.2859 × SETBP1 expression) + (0.0979 × RCOR2 expression) + (-0.1999 × CBX7 expression) + (-0.881 × SATB1 expression). BLCA patients were classified into two groups (high-risk groups and low-risk groups) in line with the median risk score. The deaths of the high-risk group were significantly more than those of the low-risk group (p < 0.001), which suggested that risk score was negatively correlated with prognosis (Figure 3A, and C). The time-dependent ROC analysis showed that the prognostic accuracy of the CR-based signature in the TCGA dataset was 0.686 at 5-year (Figure 3B). We also validated the prognostic value of the CR-based signature in the GEO dataset in the same method. The result was consistent with the TCGA dataset (Figure 4A, and C). The time-dependent ROC curve showed the AUCs was 0.769 at 5-years (Figure 4B).

Figure 1
figure 1

Heatmap showed differentially expressed CRs

Figure 2
figure 2

Identification of prognostic CRs by univariate Cox regression analysis

Table 1 Gene list and coefficient
Figure 3
figure 3

Construction of the prognostic CR-based signature in TCGA set. A. Kaplan-Meier survival analysis of BLCA patients between high-risk groups and low-risk groups in TCGA set; B. Time-independent receiver operating characteristic (ROC) analysis of risk scores predicting the overall survival in TCGA set; C. Distribution of survival status based on the median risk score in TCGA set; D. Heatmap showed the differences of 11 chromatin regulators between high and low-risk patients in TCGA set

Figure 4
figure 4

Validation of the prognostic CR-based signature in the GSE13507 set. A. Kaplan-Meier survival analysis of BLCA patients between high-risk groups and low-risk groups in GSE13507 set; B. Time-independent receiver operating characteristic (ROC) analysis of risk scores predicting the overall survival in GSE13507 set; C. Distribution of survival status based on the median risk score in GSE13507 set; D. Heatmap showed the differences of 11 chromatin regulators between high and low-risk patients in GSE13507 set

The CR-based signature was an independent indicator of BLCA prognosis

We executed univariable and multivariable Cox analyses to testify whether this signature could be an independent prognostic indicator. Univariate analysis showed that risk score, TNM stage, N stage, T stage, and age were significantly relevant to the survival of BLCA patients (p < 0.001) (Figure 5A). Multivariate analysis indicated that the risk score, N stage, and age were still remarkably related to prognosis (p < 0.05) (Figure 5B). These results demonstrated that CR-based signature was an independent prognostic indicator for BLCA patients.

Figure 5
figure 5

The signature was an independent prognostic factor for BLCA in the TCGA set. (A) The correlations between the risk score for OS and clinicopathological factors by univariate Cox regression analysis; (B) The correlations between the risk score for OS and clinicopathological factors by multivariate Cox regression analysis

Association between the signature and clinical characteristics

Chi-square test was used to explore whether the prognostic signature participated in the development and progression of BLCA. The result (Figure 6A-B) showed that there were significant differences between high- and low-risk groups in tumor grade (p < 0.001), TNM stage (p < 0.001), N stage (p < 0.01), and T stage (p < 0.001) but no significant differences in age and gender (p > 0.05). Moreover, stratification analysis was further conducted to investigated the prognostic significance of the signature in subgroups. Our research suggested that CR-based signature showed excellent performance in predicting outcome in age > 65 (p < 0.001), age <=65 (p = 0.013), female (p < 0.01), male (p < 0.001), Stage I-II (p = 0.025), Stage III-IV (p < 0.001), Grade high (p < 0.001), T3-T4 stage (p < 0.001), N0 (p < 0.001) and N1-2-3 (p = 0.018). While CR-based signature showed poor performance in predicting outcome in T1-T2 stage and Grade low (p > 0.05) (Figure 7).

Figure 6
figure 6

Correlation between signature and clinical characteristics

Figure 7
figure 7

Kaplan-Meier curves of OS differences stratified by gender, age, grade, N stage, T stage, or TNM stage between the high-risk groups and low-risk groups

Construction of a Nomogram

The nomogram incorporated various prognostic indicators to assess the survival probability of an individual graphically. To further forecast the survival of BLCA patients, we structured a nomogram comprised of N and risk score as well as age. Nomography predicted the 3-, 5-year survival rate of patients with BLCA (Figure 8A). The calibration curve indicated that the practical survival of the patient was in line with the predicted value (Figure 8B-C). The C index of the nomogram was 0.691, which confirmed the favorable prediction ability of the nomogram.

Figure 8
figure 8

Construction of a nomogram. (A) nomogram for predicting 3- or 5-year OS; (B) The calibration plots for predicting 3-year OS; (C) The calibration plots for predicting 5-year OS

Functional enrichment analyses and Protein-Protein interaction (PPI)

GO and KEGG analyses were carried out to explore the potential function of differently expressed CRs. The results of biological process analyses showed that 91 CRs were remarkablly involved in covalent chromatin modification, histone modification, DNA replication, and peptidyl lysine modification. Cellular component analysis suggested that nuclear chromosome part, chromatin, heterochromatin, chromosomal region, and PcG protein complex were mainly enriched. Molecular function analysis indicated that 91 CRs were majorly located in chromatin binding, transcription coregulator activity, histone binding, and nuclear hormone receptor binding (Figure 9A). In the KEGG pathways, the results indicated that these genes were mainly involved in the cell cycle, microRNAs in cancer, apoptosis, p53 signaling pathway, MAPK signaling pathway, and FoxO signaling pathway (Figure 9B). STRING database showed that the PPI network of the differentially expressed CRs comprised 82 nodes and 479 edges (Figure 10A). The most meaningful module consisted of 25 CRs, including 25 nodes and 266 edges (Figure 10B).

Figure 9
figure 9

Enrichment analyses of differentially expressed CRs. (A) GO analysis; (B) KEGG analysis

Figure 10
figure 10

Protein-protein interaction network of differentially expressed CRs


To further elucidate the molecular mechanisms of CR-based signature, GSEA analysis was performed. The results of GSEA analysis showed that bladder cancer, pathways in cancer, focal adhesion, GAP Junction, oocyte meiosis, chemokine signaling pathway, melanoma, WNT signaling pathway, prion disease, TGF-β signaling pathway, Hedgehog signaling pathway, and MAPK signaling pathway were mainly enriched in the high-risk group, while alpha-linolenic acid metabolism, drug metabolism cytochrome P450, oxidative phosphorylation, fatty acid metabolism, peroxisome, and retinol metabolism were mainly enriched in low-risk group (Figure 11).

Figure 11
figure 11

GSEA analysis

Immune infiltration level analysis of the CR-based signature

The relationship between the signature and immune infiltration was displayed in the heatmap according to the analyses of TIMER, CIBERSORT, CIBERSORT-ABS, XCELL, QUANTISEQ, EPIC, and MCP-counter (Figure 12). The result of CIBERSORT indicated that the proportions of CD8+ T cells, Tregs, and activated dendritic cells were higher in the low-risk group, whereas M0 macrophages and M2 macrophages had higher proportions in the high-risk groups (Supplemental Figure 3). Given the significance of checkpoint inhibitor immunotherapies, we also investigated the correlation between risk score and key immune checkpoints (PDCD1, PD-L1, LAG3, HAVCR2, TIGIT, and CTLA4). We found a prominent difference in the expression of PDCD1, PD-L1, LAG3, HAVCR2, TIGIT, and CTLA4 between the two groups of patients. In addition, PD-1, PD-L1, LAG3, HAVCR2, TIGIT, and CTLA4 were elevated in the high-risk groups, suggesting an immunosuppressive and exhausted phenotype in the high-risk groups (Figure 13).

Figure 12
figure 12

Immune cells infiltration between high-risk groups and low-risk groups

Figure 13
figure 13

The relationship between prognostic signature and immune checkpoints

Identification of small molecule drugs

We acquired the 8 most potential small molecule drugs on the basis of CRs through the CMAP database. They were phenoxybenzamine, pyrvinium, trichostatin A, ionomycin, methylbenzethonium chloride, rottlerin, lanatoside C, and monorden (Table 2).

Table 2 The 8 small molecule drugs of CMP dataset analyses results

TIMER analysis

TIMER database was applied to explore the relationship between immune cells and 11 prognostic CRs. The results showed SETBP1, ZHX3, and TCF4 were positively associated with multiple immune cells such as CD8+ T cells, CD4+ T cells, macrophage, neutrophil, and dendritic cells. HMGA1 was negatively correlated with macrophage and positively correlated with CD8+ T cells, neutrophils, and dendritic cells. SETD7 and DUSP1 were positively associated with CD8+ T cells, macrophage, neutrophils, and dendritic cells. ARID3A and RAC3 were positively related to macrophage. Meanwhile, RAC3 also was negatively related to dendritic cells. SATB1 was negatively connected with CD8+ T cell and dendritic cells while positive related to macrophage and B cell. RCOR2 was negatively connected with CD8+ T cells, neutrophils, and dendritic cells. CBX7 was positively related to CD4+ T cells, macrophage, and B cells while negatively in connection with B cell, neutrophils, and dendritic cells (Supplemental Figure 1 and Figure 2).

Drug sensitivity analysis

To advance the therapeutic effect of patients with BLCA, we further investigated the sensitivity difference of common chemotherapy drugs among two groups. The results of GDSC database analysis indicated that IC50 values of drugs including Camptothecin, Mitomycin C, Thapsigargin, Gemcitabine, Pazopanib, Docetaxel, Sunitinib, Cisplatin, and Vinblastine were higher in patients of the high-risk group than those of the low-risk group, which suggested that patients in the high-risk group were much more sensitive to these drugs (Figure 14). While IC50 values of Methotrexate and Vinorelbine were much lower in patients of the low-risk group than those of the high-risk group, suggesting that patients in the low-risk group were much more sensitive to Methotrexate and Vinorelbine.

Figure 14
figure 14

Drug sensitivity analysis


Several diagnostic and prognostic biomarkers, including mRNAs, miRNAs, lncRNAs, and circRNAs, have been identified for cancers [29,30,31,32]. Risk models with high prognostic accuracy were identified as potential prognostic biomarkers based on RNA-binding proteins in many cancer types [33,34,35]. Prognostic indicators based on long non-coding RNAs have been reported in several pieces of researches such as immune-related lncRNAs [36, 37] and autophagy-related lncRNAs [38, 39], which also showed well performance in predicting the overall survival of cancer patients. ROC curves showed that the AUC of circ_0004826 was 0.790, which suggested the availability of distinguishing cancer tissues and normal tissues [40]. A risk score model based on three miRNAs (miR-126-3p, miR-143-5p, and miR-1275) was identified as a potential biomarker for GC prognosis [41]. A growing number of studies have demonstrated that CRs exert various functions in BLCA tumorigenesis. However, few studies have comprehensively analyzed CRs to investigate the clinical significance of CRs in BLCA.

In the present study, we first screened 91 CRs that were differentially expressed between BLCA tissues and normal bladder tissues in the TCGA database. We systematically explored the biological pathways and constructed PPI networks for 91 CRs. Then, we identified 11 CRs related to BLCA prognosis through performing univariable and lasso-penalized Cox regression analyses. Based on these 11 CRs, we established and validated a risk model associated with outcome. Survival and ROC analyses have shown that the good predictive ability of the model. Finally, the results of univariable and multivariable Cox analyses have indicated that the risk score based on 11 CRs was an independent prognostic indicator for BLCA patients. Furthermore, we also found that the signature was closely related to immune cells infiltration and 8 small molecule drugs were identified for the treatment of patients with BLCA.

GO analyses uncovered that CRs were mainly related to process terms, such as covalent chromatin modification, histone modification, DNA replication, and chromatin binding. The result of pathway enrichment analyses indicated that 91 CRs were mainly involved in the cell cycle, apoptosis, p53 signaling pathway, MAPK signaling pathway, and FoxO signaling pathway. These pathways were strongly linked to malignant phenotypes of various malignancies, which implied that CRs might play critical roles in the tumorigenesis and progression of cancer. Additionally, TIMER database analyses showed that 11 prognostic CRs of the model were related to immune cell infiltration, which revealed that CRs might regulate cancer progression by influencing immune infiltration.

Zinc finger and homeobox 3 (ZHX3), a ubiquitous transcriptional repressor, has been reported to participate in various cancers, including bladder cancer [42], breast cancer [43], gastric cancer [44] and renal cancer [45]. Overexpression of ZHX3 was positively related to worse clinical characteristics including N stage and recurrence. A high ZHX3 expression was an independent factor, which indicated an unfavorable prognosis in BLCA patients. ZHX3 exerted an oncogenic role in BLCA by inhibiting the RGS2/RhoA pathway. TCF4, as an important regulator of epithelial-mesenchymal transition and downstream of the Wnt/β-catenin signaling pathway, has been reported to be involved in cancer metastasis [46]. SET binding protein 1 (SETBP1), known as PP2A phosphatase activity inhibitor, was implicated in cancer pathogenesis such as leukemic malignancies [47], colorectal cancer [48], lung cancer [49], and breast cancer [50]. Under-expression of SETBP1 promoted the proliferation and invasion of NSCLC cells through activating the ERK1/2 signaling pathway. SET domain containing 7(SETD7), a histone lysine methyltransferase, has been reported to be dysregulated in various cancers. However, several pieces of research have demonstrated that SETD7 was a tumor suppressor gene in BLCA [51]. High-mobility group A1(HMGA1) deregulated in a variety of cancers including breast cancer [52], lung cancer [53], cervical cancer [54], and bladder cancer [21]. Our previous study indicated that HMGA1 was significantly elevated in BLCA, and HMGA1 silencing could suppress tumorigenic phenotypes of BLCA cells by inhibiting the miR-221/TP53INP1 axis. Dual-specificity protein phosphatase 1 (DUSP1) was involved in proliferation, autophagy, and apoptosis through regulating MAPK and SAPK/JNK signaling pathways. DUSP1 was upregulated in BLCA tissues and inhibited cancer cells proliferation [55]. The function of Chromobox 7(CBX7) in cancer remains controversial. Some studies have shown that CBX 7 exerted anti-cancer function in many cancers. Several studies also found that CBX 7 might play an oncogenic role in multiple cancers. AT-rich interactive domain 3A (ARID3A) was considered as an independent prognostic predictor for several cancers. ARID3A facilitated the malignant phenotypes through upregulating AURKA in colorectal cancer [56]. Rac family of small GTPase 3 (RAC3), one of the Rho GTPase family members, has been reported that overexpression of RAC3 emerged in several cancers. RAC3 was also embroiled in cancer cell proliferation and aggressiveness [57, 58]. Furthermore, overexpression of RAC3 could enhance cell proliferation, migration, and invasion by activating JAK/STAT signaling in BLCA [59]. Special AT-rich sequence-binding protein-1 (SATB1) might have diverse functions in cancer dependent on tumor type and stage [60]. One study found that SATB1 knockdown in BLCA HTB-9 cells promoted cell growth and decreased sensitization to cisplatin. Meanwhile, SATB1 silencing in BLCA HTB-5 cells reduced cell proliferation and enhanced sensitization to cisplatin [61]. Another study reported that SATB1 accelerated the malignant progression of BLCA via inducing epithelial-mesenchymal transition (EMT) [62]. RCOR2 could activate LSD1, recently identified as a potent inhibitor of anti-tumor immunity [63]. RCOR2 was positively correlated with ERV, IFN, and ISG. Upregulation of RCOR2 in tumors provided a selective advantage by LSD1-mediated immune evasion [64].

The results of GSEA analysis indicated that CR-based signature was mainly implicated in cancer- and metabolism-related pathways, such as pathways in cancer, TGF-β signaling pathway, oxidative phosphorylation, fatty acid metabolism, and MAPK signaling pathway. Hence, CR-based signature has the predictive ability of prognosis in patients with BLCA and might function as a crucial role in BLCA biology.

CD8+T cells suggested a favorable prognosis and better response from pembrolizumab, which was consistent with our results that the proportions of CD8+ T cells were higher in the low-risk group. Patients with BLCA in the high-risk groups had the higher expression of PDCD1, PD-L1, Tim-3, CTLA4, TIGIT, and LAG3 than those in the low-risk groups, which indicated that the unfavorable prognosis of BLCA patients in high-risk groups might be owing to the immunosuppressive microenvironment. Moreover, BLCA patients in the high-risk groups might benefit from checkpoint inhibitor immunotherapies. In addition, we also found that BLCA patients in the high-risk group might benefit from the treatments of Camptothecin, Pazopanib, Docetaxel, Mitomycin C, Thapsigargin, Gemcitabine, Sunitinib, Cisplatin, and Vinblastine, and BLCA patients in the low-risk group might benefit from the treatments of Methotrexate and Vinorelbine.

This study also had some shortcomings. The mechanisms on how CRs regulated the biological behavior of BLCA cells should be verified by experiments. In addition, a multicenter clinical cohort should be used to verify the practicability of the prognostic model.


In conclusion, we identified differentially expressed CRs that might involve in carcinogenesis and progression of BLCA. CRs have important values in predicting the outcome of BLCA patients and targeting CRs showed the potential application as an effective treatment of bladder cancer. Our study also should be validated by further research.

Availability of data and materials

The raw data of this study are derived from the TCGA database ( and GEO data portal (, which are publicly available databases.



Bladder Cancer


Chromatin regulator


The Cancer Genome Atlas


Gene Expression Omnibus


Kyoto Encyclopedia of Genes and Genomes


False discovery rate


Fold change


Gene ontology


  1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA. Cancer J. Clin. 2021;71:7–33.

    Article  PubMed  Google Scholar 

  2. Wen J, Yang T, Mallouk N, Zhang Y, Li H, Lambert C, et al. Urinary Exosomal CA9 MRNA as a Novel Liquid Biopsy for Molecular Diagnosis of Bladder Cancer. Int. J. Nanomedicine. 2021;16:4805–11.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Piao X-M, Cha E-J, Yun SJ, Kim W-J. Role of Exosomal MiRNA in Bladder Cancer: A Promising Liquid Biopsy Biomarker. Int. J. Mol. Sci. 2021;22:1713.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Iyer G, Rosenberg JE. Novel Therapies in Urothelial Carcinoma: A Biomarker-Driven Approach. Ann. Oncol. 2018;29:2302–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ghasemzadeh A, Bivalacqua TJ, Hahn NM, Drake CG. New Strategies in Bladder Cancer: A Second Coming for Immunotherapy. Clin. Cancer Res. 2016;22:793–801.

    Article  CAS  PubMed  Google Scholar 

  6. Lodewijk I, Dueñas M, Rubio C, Munera-Maravilla E, Segovia C, Bernardini A, et al. Liquid Biopsy Biomarkers in Bladder Cancer: A Current Need for Patient Diagnosis and Monitoring. Int. J. Mol. Sci. 2018;19:2514.

    Article  CAS  PubMed Central  Google Scholar 

  7. Pond GR, Agarwal A, Ornstein M, Garcia J, Gupta R, Grivas P, et al. Clinical Outcomes of Platinum-Ineligible Patients with Advanced Urothelial Carcinoma Treated With First-Line PD1/L1 Inhibitors. Clin. Genitourin. Cancer. 2021;19:425–33.

    Article  PubMed  Google Scholar 

  8. Xie R, Chen X, Cheng L, Huang M, Zhou Q, Zhang J, et al. NONO Inhibits Lymphatic Metastasis of Bladder Cancer via Alternative Splicing of SETMAR. Mol. Ther. 2021;29:291–307.

    Article  CAS  PubMed  Google Scholar 

  9. Chen, X.; Zhang, J.; Ruan, W.; Huang, M.; Wang, C.; Wang, H.; Jiang, Z.; Wang, S.; Liu, Z.; Liu, C.; et al. Urine DNA Methylation Assay Enables Early Detection and Recurrence Monitoring for Bladder Cancer. J. Clin. Invest. 130, 6278–6289, doi:10.1172/JCI139597.

  10. Guo Y, Yin J, Dai Y, Guan Y, Chen P, Chen Y, et al. A Novel CpG Methylation Risk Indicator for Predicting Prognosis in Bladder Cancer. Front. Cell Dev. Biol. 2021;9:642650.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Damrauer JS, Roell KR, Smith MA, Sun X, Kirk EL, Hoadley KA, et al. Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non–Muscle-Invasive Bladder Cancer. Clin. Cancer Res. 2021;27:4599–609.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Lu X, Meng J, Zhu J, Zhou Y, Jiang L, Wang Y, et al. Prognosis Stratification and Personalized Treatment in Bladder Cancer through a Robust Immune Gene Pair-based Signature. Clin. Transl. Med. 2021;11:e453.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Zhang P, Liu Z, Wang D, Li Y, Xing Y, Xiao Y. Scoring System Based on RNA Modification Writer-Related Genes to Predict Overall Survival and Therapeutic Response in Bladder Cancer. Front. Immunol. 2021;12:724541.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Ruan W, Chen X, Huang M, Wang H, Chen J, Liang Z, et al. A Urine-Based DNA Methylation Assay to Facilitate Early Detection and Risk Stratification of Bladder Cancer. Clin. Epigenetics. 2021;13:91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Lu J, Xu J, Li J, Pan T, Bai J, Wang L, et al. FACER: Comprehensive Molecular and Functional Characterization of Epigenetic Chromatin Regulators. Nucleic Acids Res. 2018;46:10019–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Plass C, Pfister SM, Lindroth AM, Bogatyrova O, Claus R, Lichter P. Mutations in Regulators of the Epigenome and Their Connections to Global Chromatin Patterns in Cancer. Nat. Rev. Genet. 2013;14:765–80.

    Article  CAS  PubMed  Google Scholar 

  17. Marazzi I, Greenbaum BD, Low DHP, Guccione E. Chromatin Dependencies in Cancer and Inflammation. Nat. Rev. Mol. Cell Biol. 2018;19:245–61.

    Article  CAS  PubMed  Google Scholar 

  18. Li T, Yang J, Yang B, Zhao G, Lin H, Liu Q, et al. Ketamine Inhibits Ovarian Cancer Cell Growth by Regulating the LncRNA-PVT1/EZH2/P57 Axis. Front. Genet. 2021;11:597467.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Chu Y, Chen W, Peng W, Liu Y, Xu L, Zuo J, et al. Amnion-Derived Mesenchymal Stem Cell Exosomes-Mediated Autophagy Promotes the Survival of Trophoblasts Under Hypoxia Through MTOR Pathway by the Downregulation of EZH2. Front. Cell Dev. Biol. 2020;8:545852.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Chen J, Wang F, Xu H, Xu L, Chen D, Wang J, et al. Long Non-Coding RNA SNHG1 Regulates the Wnt/β-Catenin and PI3K/AKT/MTOR Signaling Pathways via EZH2 to Affect the Proliferation, Apoptosis, and Autophagy of Prostate Cancer Cell. Front. Oncol. 2020;10:552907.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Liu X, Zhou Z, Wang Y, Zhu K, Deng W, Li Y, et al. Downregulation of HMGA1 Mediates Autophagy and Inhibits Migration and Invasion in Bladder Cancer via MiRNA-221/TP53INP1/p-ERK Axis. Front. Oncol. 2020;10:589.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Huang Z, Yan Y, Zhu Z, Liu J, He X, Dalangood S, et al. CBX7 Suppresses Urinary Bladder Cancer Progression via Modulating AKR1B10–ERK Signaling. Cell Death Dis. 2021;12:537.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Chen X, Xie W, Gu P, Cai Q, Wang B, Xie Y, et al. Upregulated WDR5 Promotes Proliferation, Self-Renewal and Chemoresistance in Bladder Cancer via Mediating H3K4 Trimethylation. Sci. Rep. 2015;5:8293.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Yeh C-M, Chen P-C, Hsieh H-Y, Jou Y-C, Lin C-T, Tsai M-H, et al. Methylomics Analysis Identifies ZNF671 as an Epigenetically Repressed Novel Tumor Suppressor and a Potential Non-Invasive Biomarker for the Detection of Urothelial Carcinoma. Oncotarget. 2015;6:29555–72.

    Article  Google Scholar 

  25. Behrens C, Solis LM, Lin H, Yuan P, Tang X, Kadara H, et al. EZH2 Protein Expression Associates With the Early Pathogenesis, Tumor Progression and Prognosis of Non-Small Cell Lung Carcinoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2013;19:6556–65.

    Article  CAS  Google Scholar 

  26. Au SL-K, Wong CC-L, Lee JM-F, Fan DN-Y, Tsang FH, Ng IO-L, et al. Enhancer of Zeste Homolog 2 Epigenetically Silences Multiple Tumor Suppressor MicroRNAs to Promote Liver Cancer Metastasis. Hepatology. 2012;56:622–31.

    Article  CAS  PubMed  Google Scholar 

  27. Li Z, Hou P, Fan D, Dong M, Ma M, Li H, et al. The Degradation of EZH2 Mediated by LncRNA ANCR Attenuated the Invasion and Metastasis of Breast Cancer. Cell Death Differ. 2017;24:59–71.

    Article  CAS  PubMed  Google Scholar 

  28. Kim W-J, Kim E-J, Kim S-K, Kim Y-J, Ha Y-S, Jeong P, et al. Predictive Value of Progression-Related Gene Classifier in Primary Non-Muscle Invasive Bladder Cancer. Mol. Cancer. 2010;9:3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Chen Z, Chen X, Xie R, Huang M, Dong W, Han J, et al. DANCR Promotes Metastasis and Proliferation in Bladder Cancer Cells by Enhancing IL-11-STAT3 Signaling and CCND1 Expression. Mol. Ther. 2019;27:326–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Jin M, Lu S, Wu Y, Yang C, Shi C, Wang Y, et al. Hsa_circ_0001944 Promotes the Growth and Metastasis in Bladder Cancer Cells by Acting as a Competitive Endogenous RNA for MiR-548. J. Exp. Clin. Cancer Res. CR. 2020;39:186.

    Article  CAS  PubMed  Google Scholar 

  31. Chen X, Xie R, Gu P, Huang M, Han J, Dong W, et al. Long Noncoding RNA LBCS Inhibits Self-Renewal and Chemoresistance of Bladder Cancer Stem Cells through Epigenetic Silencing of SOX2. Clin. Cancer Res. 2019;25:1389–403.

    Article  CAS  PubMed  Google Scholar 

  32. Chang Y, Jin H, Li H, Ma J, Zheng Z, Sun B, et al. MiRNA-516a Promotes Bladder Cancer Metastasis by Inhibiting MMP9 Protein Degradation via the AKT/FOXO3A/SMURF1 Axis. Clin. Transl. Med. 2020;10:e263.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. He, C. Establishment and Validation of an RNA Binding Protein-Associated Prognostic Model for Ovarian Cancer. 2021, 11.

  34. Wang Z, Tang W, Yuan J, Qiang B, Han W, Peng X. Integrated Analysis of RNA-Binding Proteins in Glioma. Cancers. 2020;12:892.

    Article  CAS  PubMed Central  Google Scholar 

  35. Wu Y, Liu Y, He A, Guan B, He S, Zhang C, et al. Identification of the Six-RNA-Binding Protein Signature for Prognosis Prediction in Bladder Cancer. Front. Genet. 2020;11:992.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Wang, Y.; Ba, H.-J.; Wen, X.-Z.; Zhou, M.; Küçük, C.; Tamagnone, L.; Wei, L.; You, H. A Prognostic Model for Melanoma Patients on the Basis of Immune-Related LncRNAs. Aging 2021, 13, 6554–6564, doi:10.18632/aging.202730.

  37. Wang J, Yin X, Zhang Y-Q, Ji X. Identification and Validation of a Novel Immune-Related Four-LncRNA Signature for Lung Adenocarcinoma. Front. Genet. 2021;12:639254.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Lai, C.; Wu, Z.; Shi, J.; Li, K.; Zhu, J.; Chen, Z.; Liu, C.; Xu, K. Autophagy-Related Long Noncoding RNAs Can Predict Prognosis in Patients with Bladder Cancer. Aging 2020, 12, 21582–21596, doi:10.18632/aging.103947.

  39. Wu, Q.; Li, Q.; Zhu, W.; Zhang, X.; Li, H. Identification of Autophagy-related Long Non-coding RNA Prognostic Signature for Breast Cancer. J. Cell. Mol. Med. 2021, jcmm.16378, doi:10.1111/jcmm.16378.

  40. Shen C, Wu Z, Wang Y, Gao S, Da L, Xie L, et al. Downregulated Hsa_circ_0077837 and Hsa_circ_0004826, Facilitate Bladder Cancer Progression and Predict Poor Prognosis for Bladder Cancer Patients. Cancer Med. 2020;9:3885–903.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Qi W, Zhang Q. Development and Clinical Validation of a 3-MiRNA Signature to Predict Prognosis of Gastric Cancer. PeerJ. 2021;9:e10462.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Deng M, Wei W, Duan J, Chen R, Wang N, He L, et al. ZHX3 Promotes the Progression of Urothelial Carcinoma of the Bladder via Repressing of RGS2 and Is a Novel Substrate of TRIM21. Cancer Sci. 2021;112:1758–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. You Y, Ma Y, Wang Q, Ye Z, Deng Y, Bai F. Attenuated ZHX3 Expression Serves as a Potential Biomarker That Predicts Poor Clinical Outcomes in Breast Cancer Patients. Cancer Manag. Res. 2019;11:1199–210.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. You Y, Bai F, Li H, Ma Y, Yao L, Hu J, et al. Prognostic Value and Therapeutic Implications of ZHX Family Member Expression in Human Gastric Cancer. Am. J. Transl. Res. 2020;12:3376–88.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Kwon R-J, Kim YH, Jeong DC, Han M-E, Kim J-Y, Liu L, et al. Expression and Prognostic Significance of Zinc Fingers and Homeoboxes Family Members in Renal Cell Carcinoma. PLOS ONE. 2017;12:e0171036.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Xiao Y-Y, Lin L, Li Y-H, Jiang H-P, Zhu L-T, Deng Y-R, et al. ZEB1 Promotes Invasion and Metastasis of Endometrial Cancer by Interacting with HDGF and Inducing Its Transcription. Am. J. Cancer Res. 2019;9:2314–30.

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Cristóbal I, Blanco FJ, Garcia-Orti L, Marcotegui N, Vicente C, Rifon J, et al. SETBP1 Overexpression Is a Novel Leukemogenic Mechanism That Predicts Adverse Outcome in Elderly Patients with Acute Myeloid Leukemia. Blood. 2010;115:615–25.

    Article  CAS  PubMed  Google Scholar 

  48. Torrejón B, Cristóbal I, Caramés C, Prieto-Potín I, Chamizo C, Santos A, et al. Analysis of Potential Alterations Affecting SETBP1 as a Novel Contributing Mechanism to Inhibit PP2A in Colorectal Cancer Patients. World J. Surg. 2018;42:3771–8.

    Article  PubMed  Google Scholar 

  49. Li H-R, Gao J, Jin C, Jiang J-H, Ding J-Y. Downregulation of SETBP1 Promoted Non-Small Cell Lung Cancer Progression by Inducing Cellular EMT and Disordered Immune Status. Am. J. Transl. Res. 2020;12:447–62.

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Chen L, Zhang Z, Yi Z, Li J. MicroRNA-211-5p Suppresses Tumour Cell Proliferation, Invasion, Migration and Metastasis in Triple-Negative Breast Cancer by Directly Targeting SETBP1. Br. J. Cancer. 2017;117:78–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Xie H, Li J, Ying Y, Yan H, Jin K, Ma X, et al. METTL3/YTHDF2 M6A Axis Promotes Tumorigenesis by Degrading SETD7 and KLF4 MRNAs in Bladder Cancer. J. Cell. Mol. Med. 2020;24:4092–104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Méndez O, Pérez J, Soberino J, Racca F, Cortés J, Villanueva J. Clinical Implications of Extracellular HMGA1 in Breast Cancer. Int. J. Mol. Sci. 2019;20:5950.

    Article  CAS  PubMed Central  Google Scholar 

  53. Hillion J, Wood LJ, Mukherjee M, Bhattacharya R, Cello FD, Kowalski J, et al. Up-Regulation of MMP-2 by HMGA1 Promotes Transformation in Undifferentiated. Large Cell Lung Cancer. Mol. Cancer Res. MCR. 2009;7:1803.

    Article  CAS  PubMed  Google Scholar 

  54. Fu F, Wang T, Wu Z, Feng Y, Wang W, Zhou S, et al. HMGA1 Exacerbates Tumor Growth through Regulating the Cell Cycle and Accelerates Migration/Invasion via Targeting MiR-221/222 in Cervical Cancer. Cell Death Dis. 2018;9:594.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Cai X, Qu L, Yang J, Xu J, Sun L, Wei X, et al. Exosome–Transmitted MicroRNA-133b Inhibited Bladder Cancer Proliferation by Upregulating Dual-specificity Protein Phosphatase 1. Cancer Med. 2020;9:6009–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Tang J, Yang L, Li Y, Ning X, Chaulagain A, Wang T, et al. ARID3A Promotes the Development of Colorectal Cancer by Upregulating AURKA. Carcinogenesis. 2021;42:578–86.

    Article  CAS  PubMed  Google Scholar 

  57. Donnelly SK, Cabrera R, Mao SPH, Christin JR, Wu B, Guo W, et al. Rac3 Regulates Breast Cancer Invasion and Metastasis by Controlling Adhesion and Matrix Degradation. J. Cell Biol. 2017;216:4331–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Song X, Chen H, Zhang C, Yu Y, Chen Z, Liang H, et al. SRC-3 Inhibition Blocks Tumor Growth of Pancreatic Ductal Adenocarcinoma. Cancer Lett. 2019;442:310–9.

    Article  CAS  PubMed  Google Scholar 

  59. Cheng C, Song D, Wu Y, Liu B. RAC3 Promotes Proliferation, Migration and Invasion via PYCR1/JAK/STAT Signaling in Bladder Cancer. Front. Mol. Biosci. 2020;7:218.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Glatzel-Plucińska N, Piotrowska A, Dzięgiel P, Podhorska-Okołów M. The Role of SATB1 in Tumour Progression and Metastasis. Int. J. Mol. Sci. 2019;20:4156.

    Article  CAS  PubMed Central  Google Scholar 

  61. Choudhary, D.; Clement, J.M.; Choudhary, S.; Voznesensky, O.; Pilbeam, C.C.; Woolbright, B.L.; Taylor, J.A. SATB1 and Bladder Cancer: Is There a Functional Link? Urol. Oncol. Semin. Orig. Investig. 2018, 36, 93.e13-93.e21, doi:10.1016/j.urolonc.2017.10.004.

  62. Wan F, Cheng C, Wang Z, Xiao X, Zeng H, Xing S, et al. SATB1 Overexpression Regulates the Development and Progression in Bladder Cancer through EMT. PLOS ONE. 2015;10:e0117518.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Xiong Y, Wang L, Di Giorgio E, Akimova T, Beier UH, Han R, et al. Inhibiting the Coregulator CoREST Impairs Foxp3+ Treg Function and Promotes Antitumor Immunity. J. Clin. Invest. 1830–1842;130.

  64. Park DE, Cheng J, McGrath JP, Lim MY, Cushman C, Swanson SK, et al. Merkel Cell Polyomavirus Activates LSD1-Mediated Blockade of Non-Canonical BAF to Regulate Transformation and Tumorigenesis. Nat. Cell Biol. 2020;22:603–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references


Not applicable.


This work was supported by grants from the National Natural Science Foundation of China (No: 81960512).

Author information

Authors and Affiliations



KZ, LX and WD designed the research study. LX and WD took responsibility for statistical analyses. KZ wrote the manuscrfipt. WG and BF evaluated and revised the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Gongxian Wang or Bin Fu.

Ethics declarations

Ethical approval and Consent to participate

This article does not contain any studies with human participants or animals performed by any of the authors.

Consent for publication

All authors consent to the publication of this study.

Competing interests

No competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Supplemental Figure 1

Immune cells infiltration of 11 CRs by TIMER database.

Additional file 2: Supplemental Figure 2

Immune cells infiltration of 11 CRs by TIMER database.

Additional file 3: Supplemental Figure 3

The difference of immune cells between two groups by CIBERSORT.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhu, K., Liu, X., Deng, W. et al. Identification of a chromatin regulator signature and potential candidate drugs for bladder cancer. Hereditas 159, 13 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: